FNCH — Finch Therapeutics Cashflow Statement
0.000.00%
- $19.43m
- $3.39m
- $0.11m
- 25
- 30
- 51
- 26
Annual cashflow statement for Finch Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.8 | -39.3 | -58.2 | -115 | -74.8 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.746 | 3.11 | 3.24 | 35.9 | 50.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.21 | 4.11 | -14.5 | -1.56 | -5.42 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -17.3 | -31.3 | -67.1 | -74.9 | -31.5 |
| Capital Expenditures | -1 | -2.63 | -16 | -2.18 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.032 | 0 | 0.062 | 0 | 1.33 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.973 | -2.63 | -15.9 | -2.18 | 1.33 |
| Financing Cash Flow Items | 0 | -0.249 | 0.39 | -0.132 | -1.16 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 53.3 | 91.5 | 119 | 14.9 | -16.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 35 | 57.5 | 36.1 | -62.2 | -46.3 |